Insight

Neeraj Agarwal on T-cell engager therapies – Prostate Cancer Foundation

Neeraj Agarwal from primeinc.org

Dec 4, 2024, 17:57

Neeraj Agarwal on T-cell engager therapies – Prostate Cancer Foundation

Prostate Cancer Foundation posted the following on X:

“T-cell engager therapies act like a bridge, connecting immune cells to cancer cells. Half of patients in the early trial of a STEAP-1-targeting agent had PSA50 response. Phase 3 trials now at multiple centers.

Neeraj Agarwal explains in our latest webinar.”

cancer Neeraj Agarwal OncoDaily Oncology Phase 3 trials prostate cancer Prostate Cancer Foundation PSA50 response STEAP-1-targeting agent T-cell engager therapies

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology

Monica Bertagnolli: 2024 Science Highlights from the NIH Director’s Blog

365 Days of OncoDaily: Ending 2024 Strong

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage